Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)

Lamk M. Lamki, James L. Murray, Michael G. Rosenblum, Yehuda Z. Patt, Richard Babaian, Michael W. Unger

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.

Original languageEnglish
Pages (from-to)553-564
Number of pages12
JournalNuclear Medicine Communications
Volume9
Issue number8
Publication statusPublished - 1988

Fingerprint

Monoclonal Antibodies
Antibodies
Melanoma
Pharmacokinetics
Liver
Colonic Neoplasms
Half-Life
Neoplasms
Prostatic Neoplasms
Spleen
Molecular Weight
Neoplasm Metastasis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Lamki, L. M., Murray, J. L., Rosenblum, M. G., Patt, Y. Z., Babaian, R., & Unger, M. W. (1988). Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb). Nuclear Medicine Communications, 9(8), 553-564.

Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb). / Lamki, Lamk M.; Murray, James L.; Rosenblum, Michael G.; Patt, Yehuda Z.; Babaian, Richard; Unger, Michael W.

In: Nuclear Medicine Communications, Vol. 9, No. 8, 1988, p. 553-564.

Research output: Contribution to journalArticle

Lamki, LM, Murray, JL, Rosenblum, MG, Patt, YZ, Babaian, R & Unger, MW 1988, 'Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)', Nuclear Medicine Communications, vol. 9, no. 8, pp. 553-564.
Lamki, Lamk M. ; Murray, James L. ; Rosenblum, Michael G. ; Patt, Yehuda Z. ; Babaian, Richard ; Unger, Michael W. / Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb). In: Nuclear Medicine Communications. 1988 ; Vol. 9, No. 8. pp. 553-564.
@article{f900654c191a4d208e8a0953faea54a3,
title = "Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)",
abstract = "We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.",
author = "Lamki, {Lamk M.} and Murray, {James L.} and Rosenblum, {Michael G.} and Patt, {Yehuda Z.} and Richard Babaian and Unger, {Michael W.}",
year = "1988",
language = "English",
volume = "9",
pages = "553--564",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of111indium labelled (MoAb)

AU - Lamki, Lamk M.

AU - Murray, James L.

AU - Rosenblum, Michael G.

AU - Patt, Yehuda Z.

AU - Babaian, Richard

AU - Unger, Michael W.

PY - 1988

Y1 - 1988

N2 - We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.

AB - We have evaluated immunoscintigraphy in cancer patients using four111In-labelled murine monoclonal antibodies (MoAb): 96.5 (anti-P97 of melanoma), ZME-018 (anti-high molecular weight antibody of melanoma), ZCE-025 (anti-CEA for colon cancer) and PAY-276 (anti-prostatic acid phosphatase for prostatic cancer). The effect of increasing the doses of unlabelled MoAb (co-infused with 1 mg labelled MoAb) on the relative body distribution of each labelled MoAb was assessed. Localization in the liver decreased significantly in all cases, with increasing MoAb dose, except for ZME-018. Localization in other organs increased significantly as the liver activity decreased. The spleen activity, however, fell in the case of MoAb ZME-018. Blood-pool activity increased with MoAb dose in all four MoAbs. These findings correlated with the rise in the detection rate of metastases, the plasma half-life, and other pharmacokinetic parameters. However, the dose level at which this correlation occurred varied with each antibody. These data demonstrate that co-infusion of unlabelled MoAb with111In-labelled MoAb could alter the organ distribution, pharmacokinetics and tumour uptake in a favourable manner, though the degree to which this occurs depends on the antibody in question.

UR - http://www.scopus.com/inward/record.url?scp=0023719734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023719734&partnerID=8YFLogxK

M3 - Article

C2 - 3173914

AN - SCOPUS:0023719734

VL - 9

SP - 553

EP - 564

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 8

ER -